Summary Serum levels of mammary serum antigen (MSA) and CA15-3 were evaluated in 135 individuals in order to determine their single and combined value in the diagnosis and monitoring of breast cancer. Raised MSA levels (>300 IU) were found in 68% of patients with Stage I and II breast cancer compared to only 3% having raised CA15-3 levels (>40Uml-1). Of 38 patients with Stage IV breast cancer, 95% had raised levels of MSA and CA15-3 combined with each test individually detecting 82% of those with Stage IV disease. No correlation was found between MSA and CA15-3 levels. Four patients being treated for breast cancer were followed over a 5-17 week period; MSA levels correlated with disease course in 3 and CA-15 in 2. The overall sensitivity, specificity and accuracy in detecting breast cancer were 76%, 91% and 96% for MSA; and 47%, 95% and 97% for CA15-3 respectively. When both tests were used together combined evaluation gave the highest sensitivity (84%) and specificity (100%). MSA seems to be superior to CA15-3 for early breast cancer diagnosis and a combination of the two tests gave the best results for metastatic disease.
A suitable test for monitoring the course or to assist in the diagnosis of all patients with breast cancer has not yet been described. Currently, carcinoembryonic antigen (CEA) is the most widely used antibody based clinical assay for breast cancer, however, this has only been of limited value, as less than 25% of patients with localised disease and 50% of those with metastatic disease have elevated CEA levels (Beard & Haskell, 1986) . The advent of hybridoma technology (Kohler & Milstein, 1975) has led to the description of numerous human breast cancer-associated antigens defined by monoclonal antibodies (Schlom et al., 1985) . Two recently developed monoclonal antibody-based assays, detecting mammary serum antigen (MSA) and CA15-3 have been reported to be more specific markers for breast cancer (Stacker et al., 1987; Hayes et al., 1986) .
The competitive enzyme immunoassay detecting MSA utilizes the murine monoclonal antibody 3E1.2 (Stacker et al., 1985a) , which identifies a determinant present on a high molecular weight glycoprotein found in the serum of patients with breast cancer (Stacker et al., 1987) . The MSA test has been found to have sensitivity for primary and metastatic breast cancer, with raised levels found in some other malignant diseases but in less than 2% of the normal population (Stacker et al., 1987) . The CA15-3 immunoradiometric assay (Centocor, Malvern, PA.) is a sandwich assay utilizing the monoclonal antibody 11 5D8 developed by Hilkens et al. (1984) as the 'catcher' and the monoclonal antibody DF3 developed by Kufe et al. (1984) as the radiolabelled tracer. Preliminary reports indicate that the main application of the CA15-3 test was in the follow-up of patients with breast cancer (Ogawa et al., 1986) . The incidence of elevated CA15-3 levels in patients with breast cancer has been reported as varying between 0-35% for primary tumours and 68-100% for metastatic disease (Gang et al., 1985; Ogawa et al., 1986; Hayes et al., 1986) .
The aim of this present study was to assess the individual and combined value of the MSA and CA15-3 tests in the management of patients with breast cancer. (Millar et al., 1981; Beahrs & Myers, 1983 ). Serial samples from 4 patients on treatment for metastatic breast cancer were also collected over a 5-17 week month period. A more detailed description of each patient is presented in the results section of the paper.
Materials and methods

Patients
Assays and statistical analysis MSA levels were determined by the enzyme immunoassay previously described (Stacker et al., 1985b) . In brief, the test is a competitive inhibition assay using purified 3E1.2 antibody. MSA present on a solid phase immunoadsorbant was used to bind 3E1.2 previously reacted with a 1/32 dilution of patients' sera at room temperature for 3 h. After an incubation overnight at 4°C, excess serum and antibody was washed away and sheep anti-mouse horse-radish peroxidase conjugate (Amersham International, UK) added for 3 h at 37°C. Assays were developed using a 2.2, azinodi [3-ethylbenthiozoline] sulphonate (ABTS) substrate system. An arbitrary system of inhibition units (IU) was used to express the level of MSA in serum. A standard dilution of 3E1.2 and reference normal sera were used for calculation of units. Levels of MSA vary between 1-10,000IU, the latter indicating a high level of MSA present. The majority of the normal population (-98%) have levels <300IU (Stacker et al., 1987) . CA15-3 levels were determined by means of immunoradiometric assays kits (International CIS, Saint Quentin-Yvelines Cedex, France) according to the protocols provided with the kits. Correlation between CA15-3 and MSA levels was performed using the Pearson product moment correlation coefficient (Zar, 1974) .
Results MSA and CA15-3 levels in serum samples Levels of MSA and CA15-3 were determined in 131 serum samples from normal individuals and patients with breast tumours (Table I, Figures 1 & 2) . Arbitrary cut off values of 40 U ml-1 and 300 IU respectively were assigned for the CA15-3 and MSA testing. These values were used as they gave a 3% false positive rate (this is similar to that published in other studies). Levels of both markers for apparently normal females were of the expected low levels (mean levels were 116+751IU for MSA and 18+9Uml-1 for CA15-3). Table I illustrates the evaluation of the samples tested using a more stringent cut off limit for MSA. Here, benign conditions can be excluded by raising the cut off level to 400IU.
Of the 13 samples from patients with histologically confirmed benign breast disease, only one had a slightly elevated MSA level (388 IU). None of the 13 patients had levels of CA1 5-3 > 40 U ml -1. Interestingly, the mean CA1 5-3 level seen in patients with benign breast disease was much lower than the level of the normal subjects (see Table I ). This is in contrast to MSA levels where the reverse was the case.
Analysis of 34 patients with clinically stage I and II breast cancer revealed raised MSA levels (>300IU) in 68% (23/34) whereas CA15-3 was elevated (>40Uml-1) in only 1/34 patients. The mean level for this group were 17+8Uml-1 for CA15-3 compared to 578+534IU for MSA. The mean MSA level for this group was therefore substantially raised when compared to that of the normal population.
Significantly, more patients with Stage III and IV breast cancer had raised levels of both MSA and CA15-3 (Table I Figure 2) . It is interesting to note that 4 patients with advanced breast cancer had a raised MSA level but normal CA15-3, and 5 patients had a raised CA15-3 level but normal MSA level. This suggests that both the antigenic determinant detected by the two tests is different, and that they may be of additive value in the management of breast cancer patients. A correlation was found between CA15-3 and MSA levels in patients with metastatic disease (MSA level >500 IU, r=0.702, P<0.001), although this is probably due to the advanced stage of disease in these patients, all or most of whom have high antigen levels. In patients with Stage IV disease and MSA levels <500IU there was no correlation with the CA15-3 levels in individual patients.
MSA and CA15-3 for monitoring of disease progress MSA and CA15-3 levels were determined in four patients followed over a period of 5-17 weeks. The group consisted of three patients with Stage IV disease undergoing therapy (A, B and C) and one patient with primary breast cancer undergoing surgery followed by adjuvant chemotherapy (D) (Figure 3 Patient D A patient with primary breast cancer before mastectomy showed elevated levels of both CA15-3 and MSA. After mastectomy the patient was given adjuvant chemotherapy for Stage II disease. During this period the levels of both MSA and CA15-3 dropped significantly. By 6 weeks the CA15-3 level had fallen below 40 U ml-1 and the MSA level was marginally above the normal range. Over the next 6 months, CA15-3 level remained within the normal range and MSA levels were slightly raised despite the absence of measurable metastatic disease.
Assay parameters
The assay parameters were determined as shown in Table II . Specificity is defined as the fraction of a non-cancer population not positive at the selected cut off level, whereas sensitivity is the fraction of a cancer population positive at Using the cut off value of 300 IU for MSA and 40 U ml-I for CA15-3, only 3% of the normal controls tested had elevated levels in each test (i.e. 3% flase positive).
The assays performed on serum samples taken from 34 patients with Stage I and II disease prior to mastectomy showed that MSA levels were raised in 23 cases (68%). Only one patient had a raised CA15-3 level, and this patient also had a raised MSA level, findings in agreement with the recently reported studies in which raised MSA levels were seen in 53-75% of Stage I and II patients (Stacker et al., 1987 ) and CA15-3 was raised in only 0-35% (Gang et al., 1985) . This suggests that the MSA test may be a useful adjunct in diagnosing early breast cancer but that CA15-3 will not. Both CA15-3 and MSA were significantly better tests for advanced breast cancer than for localized disease. The mean levels of both assays were usually much higher in patients with Stage IV cancer, having a mean MSA of 4381 IU, and 133Uml-P for CA15-3. Although both assays detected 82% (31/38) of patients with advanced breast cancer, only 26 patients had raised levels of both. In 26% (10/38) of cases, patients had elevated levels of one or the other marker, resulting in a combined sensitivity of 98%. This implies that the detection of CA15-3 and MSA involves distinctly different antigenic determinants. Of those patients with a previous diagnosis of breast cancer (Stacker et al., unpublished data, Hayes et al., 1986) . However, in this study, only samples from healthy blood donors and patients with histologically confirmed benign breast disease were assayed and compared to samples from patients with proven breast cancer. Differentiating patients with breast cancer from normal individuals and patients with benign breast disease is most likely to be of concern to the treating physician. A false positive rate in the normal controls of 3% was accepted for both assays and those with a raised level did not subsequently have any evidence of malignant disease. If a cut-off level of 400IU is used for MSA a 0% false positive rate for normal controls and benign breast disease could be achieved.
The sensitivity of MSA determination alone (76%) was far greater than CA15-3 alone (47%), and when the two were combined sensitivity increased to 84%. Both tests had very high specificity (91% for MSA and 95% for CA15-3) and predictive value of a positive test result (96% for MSA and 97% for CA15-3). When the two assays were combined, specificity and predictive value of a positive result rose to 100%. Of course this is only a limited comparative study and these values for assay parameters must await confirmation in larger trials including those patients with non-breast diseases.
This study has shown that MSA testing should be of some value in the diagnosing of breast cancer, as 68% of Stage I and II patients had raised MSA levels. In advanced disease both tests are of similar accuracy with a combination of both tests proving additive in value with acceptable sensitivity, specificity and predictive value of close to 100%.
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